Discussing market action, and next week's Fed meeting, with Ed Yardeni, President of Yardeni Research. He thinks the market bottom happened last week.
The Fast Money traders share their final trades of the day.
The Fast Money traders take a look at today's biggest market movers.
Kleanthis Xanthopoulos, Regulus Therapeutics CEO and president, discusses the substantial reaction shown by a single dose of the company's Hepatitis-C drug.
FM trader Pete Najarian notices unusual activity in Advanced Micro Devices.
CNBC's Michelle Caruso-Cabrera reports a U.S. official has confirmed the name of the shooter in Ottawa as Michael Zehaf-Bibeau.
Paul Hickey, Bespoke Investment Group co-founder, shares his view on the market.
Dissecting what lower oil prices mean for the economy, with the Fast Money traders. Pete Najarian says headlines are leading the way.
The FMHR traders reveal their final trades.
CNBC contributor Herb Greenberg, weighs in on analyst Tim Ramey's $110 price target on Herbalife.
Shares of Herbalife have fallen more than 35 percent this year. Tim Ramey, Pivotal Research analyst, explains his $110 price target on the stock.
The FMHR traders take their positions on four stocks making news today, including Yahoo's big move after Q3 earnings.
Soc Gen has downgraded Coca-Cola to a sell rating. FMHR traders Pete Najarian and Mike Murphy, take their positions.
CNBC's Tyler Mathisen reports a gunman reportedly shot a Canadian uniformed soldier standing guard at the National War Memorial then entered the Canadian Parliament building.
Two biotech picks, with Yaron Werber, Citigroup biotech analyst.
Icahn Enterprises Carl Icahn said he thinks the high yield market is in a bubble on Tuesday. The FMHR traders, share their opinions.
The "Fast Money" traders share their final trades of the day.
Discussing your commodity playbook, with Michael McGlone, ETF Securities.
Icahn Enterprises Chairman Carl Icahn, weighs in on news Silicon Valley investor Marc Andreessen is leaving the board at eBay, as well as the management at the company.
The World Health Organization will send thousands of doses of NewLink's experimental Ebola vaccine to West Africa in January. Dr. Charles Link, NewLink Genetics Chairman, CEO & Chief Scientific Officer, provides insight to supply capabilities, as well as the company's $1 billion deal with Roche.